O
1.26
-0.01 (-0.79%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | OS Therapies Incorporated | - | - |
AIStockmoo 评分
-1.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.13 |
|
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 33.38% |
| 机构持股比例 | 1.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Howard Financial Services, Ltd. | 30 Sep 2026 | 248,001 |
| Beacon Pointe Advisors, Llc | 30 Jun 2026 | 62,507 |
| Ingalls & Snyder Llc | 30 Jun 2026 | 36,676 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合